Untreated, Uncontrolled, and Apparent Resistant Hypertension: Results of the German Health Examination Survey 2008–2011

Journal of Clinical Hypertension

Volumn 18, Issue 11, 2016, Pages 1146-1154

  Sarganas, Giselle ^a,b   Neuhauser, Hannelore K ^a,b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CONTROL; FEMALE; GENDER; GERMANY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; RISK FACTOR; SMOKING; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLASSIFICATION; CROSS-SECTIONAL STUDY; DRUG RESISTANCE; HEALTH SURVEY; MIDDLE AGED; PROCEDURES; SEXUAL DEVELOPMENT; YOUNG ADULT;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; FEMALE; GERMANY; HEALTH SURVEYS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84994129904     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12886     Document Type: Article

References (42)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
2. Blood Pressure Lowering Treatment Trialists C, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121–1123.
3. Falaschetti E, Mindell J, Knott C, et al. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014;383:1912–1919.
4. Gu Q, Burt VL, Dillon CF, et al. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126:2105–2114.
5. Wilkins K, Campbell NR, Joffres MR, et al. Blood pressure in Canadian adults. Health Rep. 2010;21:37–46.
6. Sarganas G, Knopf H, Grams D, et al. Trends in antihypertensive medication use and blood pressure control among adults with hypertension in Germany. Am J Hypertens. 2016;29:104–113.
7. ESH/ESC. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925–1938.
8. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–e526.
9. Scheidt-Nave C, Kamtsiuris P, Göwald A, et al. German health interview and examination survey for adults (DEGS)––design, objectives and implementation of the first data collection wave. BMC Public Health. 2012;12:730.
10. Gößwald A, Lange M, Kamtsiuris P, et al. DEGS: Studie zur Gesundheit Erwachsener in Deutschland. Bundesgesundheitsblatt. 2012;55:775–780.
11. Neuhauser HK, Ellert U, Thamm M, et al. Calibration of blood pressure data after replacement of the standard mercury sphygmomanometer by an oscillometric device and concurrent change of cuffs. Blood Press Monit. 2015;20:39–42.
12. Knopf H, Grams D. Medication use of adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt. 2013;56:868–877.
13. Neuhauser HK, Adler C, Rosario AS, et al. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. J Hum Hypertens. 2015;29:247–253.
14. Lampert T, Kroll L, Muters S, et al. Measurement of socioeconomic status in the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt. 2013;56:631–636.
15. Stevens PE, Levin A. Kidney disease: improving global outcomes chronic kidney disease guideline development work group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–830.
16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
17. Parikh CR, Fischer MJ, Estacio R, et al. Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity. Nephrol Dial Transplant. 2004;19:1881–1885.
18. Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158:1789–1795.
19. Reinert DF, Allen JP. The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res. 2007;31:185–199.
20. Krug S, Jordan S, Mensink GB, et al. Physical activity: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt. 2013;56:765–771.
21. Jones DW, Hall JE. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension. 2004;43:1–3.
22. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520.
23. Sakhuja A, Textor SC, Taler SJ. Uncontrolled hypertension by the 2014 evidence-based guideline: results from NHANES 2011–2012. J Hypertens. 2015;33:644–651. discussion 52.
24. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–1058.
25. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076–1080.
26. Gee ME, Bienek A, McAlister FA, et al. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol. 2012;28:375–382.
27. Brambilla G, Bombelli M, Seravalle G, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013;31:2018–2024.
28. de la Sierra A, Banegas JR, Oliveras A, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens. 2012;30:1211–1216.
29. Rimoldi SF, Messerli FH, Bangalore S, et al. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015;36:2686–2695.
30. Lotufo PA, Pereira AC, Vasconcellos PS, et al. Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Hypertens (Greenwich). 2015;17:74–80.
31. Weitzman D, Chodick G, Shalev V, et al. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension. 2014;64:501–507.
32. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957–1963.
33. Moser M, Cushman W, Handler J. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006;8:434–440.
34. Kjeldsen SE, Julius S, Dahlof B, et al. Physician (investigator) inertia in apparent treatment-resistant hypertension––insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. Blood Press. 2015;24:1–6.
35. Escobar C, Barrios V, Alonso-Moreno FJ, et al. Evolution of therapy inertia in primary care setting in Spain during 2002-2010. J Hypertens. 2014;32:1138–1145. discussion 45.
36. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–1642.
37. Sarafidis PA, Georgianos PI, Zebekakis PE. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin Nephrol. 2014;34:483–491.
38. Rossignol P, Massy ZA, Azizi M, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386:1588–1598.
39. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481–490.
40. Gil-Guillen V, Orozco-Beltran D, Perez RP, et al. Clinical inertia in diagnosis and treatment of hypertension in primary care: quantification and associated factors. Blood Press. 2010;19:3–10.
41. Hanselin MR, Saseen JJ, Allen RR, et al. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58:1008–1013.
42. Kamtsiuris P, Lange M, Hoffmann R, et al. The first wave of the German Health Interview and Examination Survey for Adults (DEGS1): sample design, response, weighting and representativeness. Bundesgesundheitsblatt. 2013;56:620–630.